All articles tagged: Multiple myeloma not having achieved remission (C90.00)

For patients with type 2 diabetes (T2D), glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a reduced risk for 10 of 13 obesity-associated cancers (OACs) compared with insulin, according to a study published online July 5 in JAMA Network Open.Lindsey Wang, from Case Western Reserve University School of Medicine

First-line ibrutinib is associated with better outcomes than chemoimmunotherapy among patients with chronic lymphocytic leukemia (CLL), according to a study published online May 13 in Clinical Lymphoma, Myeloma & Leukemia.Nilanjan Ghosh, M.D., Ph.D., from the Levine Cancer Institute in Charlotte, North Carolina, and colleagues condu

The prestigious Dana Farber Cancer Institute in Boston will retract six studies and correct 31 more as part of an ongoing investigation into claims of data manipulation.The action follows allegations that a British molecular biologist posted in a blog</

For individuals at increased risk for multiple myeloma, risk factors associated with mass spectrometry (MS) monoclonal gammopathy of undetermined significance (MGUS) include obesity, heavy smoking, and short sleep duration, according to a study published online Jan. 11 in Blood Advances.David J. Lee, M.D., from Massachusetts General Hos

The annual meeting of the American Society of Hematology was held from Dec. 9 to 12 in San Diego and attracted participants from around the world, including hematology specialists as well as clinical practitioners and other health care professionals. The conference featured presentations focusing on the diagnosis, treatment, and

A robust score can identify patients with newly diagnosed multiple myeloma (NDMM) at risk for severe infection/death, according to a study published online Dec. 7 in Leukemia.Elias K. Mai, M.D., from the University Hospital Heidelberg in Germany, and colleagues examined 3,700 transplant-eligible NDMM patients treated in 2005 to 2020 wi

For transplantation-eligible patients with newly diagnosed multiple myeloma, the addition of subcutaneous daratumumab combined with bortezomib, lenalidomide, and dexamethasone induction and consolidation therapy and with lenalidomide maintenance therapy (D-VRd) improves progression-free survival. These findings were published online Dec. 12 in the <

Increasing body mass index (BMI) at age 18 years is associated with development of subsequent site-specific cancers in men, according to a study published online Nov. 6 in&nbsp;Obesity.Aron Onerup, M.D., Ph.D., from the University of Gothenburg in Sweden, and colleagues examined BMI at age 18 years and incident site-specific cancer (